Obesity: CB1R inverse agonistsg - Antiobesity effects without the neuropsychiatric adverse effects?

Nature Reviews Endocrinology

Volumn 8, Issue 10, 2012, Pages 564-

  Wilson, Carol ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; IBIPINABANT; INSULIN; JD 5037; LEPTIN; RIMONABANT; UNCLASSIFIED DRUG;

ADIPOCYTE; ANXIETY DISORDER; APPETITE; BODY WEIGHT; DEPRESSION; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG PENETRATION; FATTY LIVER; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; NONHUMAN; NOTE; OBESITY; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; WEIGHT REDUCTION;

EID: 84866610044     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.145     Document Type: Note

References (1)

1. Tam, J. et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metabolism doi:10.1016/j.cmet.2012. 07.002